Scott Hensley on Muck Rack

Scott Hensley Verified

Washington, D.C.
Health Blogger and Editor — NPR

Writer and editor for Shots, NPR's health blog. Ex-WSJ. My fixations manifested here. And, yes, there will be typos. (PR people, don't pitch me on Twitter.)

A Worry In Theory, Medical Data Privacy Draws A Yawn In Practice

wabe.org — When it comes to health records, how concerned are Americans about what happens to their personal information? We asked in the latest NPR-Truven Health Analytics Health Poll. And, in a bit of surprise to me, the responses showed that, in general, worries don't run very high.

A Worry In Theory, Medical Data Privacy Draws A Yawn In Practice

kuow.org — When it comes to health records, how concerned are Americans about what happens to their personal information? We asked in the latest NPR-Truven Health Analytics Health Poll. And, in a bit of surprise to me, the responses showed that, in general, worries don't run very high.

A Worry In Theory, Medical Data Privacy Draws A Yawn In Practice

kcur.org — When it comes to health records, how concerned are Americans about what happens to their personal information? We asked in the latest NPR-Truven Health Analytics Health Poll. And, in a bit of surprise to me, the responses showed that, in general, worries don't run very high.

A Worry In Theory, Medical Data Privacy Draws A Yawn

wvpublic.org — When it comes to health records, how concerned are Americans about what happens to their personal information? We asked in the latest NPR-Truven Health Analytics Health Poll. And, in a bit of surprise to me, the responses showed that, in general, worries don't run very high.

A Worry In Theory, Medical Data Privacy Draws A Yawn

wnyc.org — When it comes to health records, how concerned are Americans about what happens to their personal information? We asked in the latest NPR-Truven Health Analytics Health Poll. And, in a bit of surprise to me, the responses showed that, in general, worries don't run very high.

A Worry In Theory, Medical Data Privacy Draws A Yawn

npr.org — When it comes to health records, how concerned are Americans about what happens to their personal information? We asked in the latest NPR-Truven Health Analytics Health Poll. And, in a bit of surprise to me, the responses showed that, in general, worries don't run very high.

Gilead Buys Shortcut For FDA Drug Review For $125 Million

kcur.org — How much is a fast track for the Food and Drug Administration review of a new drug worth? Try $125 million. In an auction, Gilead Sciences, a maker of HIV and hepatitis medicines, just bought a coupon good for the accelerated review of a drug of the company's choice from Knight Therapeutics, a Canadian company.

Gilead buys shortcut for FDA drug review for $125 million

scpr.org — How much is a fast track for the Food and Drug Administration review of a new drug worth? Try $125 million. In an auction, Gilead Sciences, a maker of HIV and hepatitis medicines, just bought a coupon good for the accelerated review of a drug of the company's choice from Knight Therapeutics, a Canadian company.

Gilead Buys Shortcut For FDA Drug Review For $125 Million

wabe.org — How much is a fast track for the Food and Drug Administration review of a new drug worth? Try $125 million. In an auction, Gilead Sciences, a maker of HIV and hepatitis medicines, just bought a coupon good for the accelerated review of a drug of the company's choice from Knight Therapeutics, a Canadian company.

Gilead Buys Shortcut For FDA Drug Review For $125 Million

kuow.org — How much is a fast track for the Food and Drug Administration review of a new drug worth? Try $125 million. In an auction, Gilead Sciences, a maker of HIV and hepatitis medicines, just bought a coupon good for the accelerated review of a drug of the company's choice from Knight Therapeutics, a Canadian company.
More Articles →
Nov 26, 2014

So fun. RT @markmemmottnpr: Alice's Restaurant became 'Thanksgiving ballad more than an anti-war this or a pro-that.' tinyurl.com/dyzw5

Nov 26, 2014

Nasal naloxone price about to double. @KristinaMFiore reports on why that's a problem: bit.ly/1vO3ZBN

Nov 25, 2014

@Skepticscalpel @gruntdoc How many radiologists want to talk to patients? Bueller? Feel-good fantasy just in time for @RSNA.

Nov 25, 2014

Case of rare brain infection reported for Biogen MS drug Tecfidera go.usa.gov/H8WP via @FDAMedWatch $BIIB

Nov 25, 2014

@USATODAYhealth Ha. That and $4 will get you a fancy coffee. I'm bracing for the PR deluge. (Please, PR people, don't pitch me here.)

Nov 25, 2014

.@NYTimes hires @kinseywilson to oversee innovation and strategy. Congrats to him and NYT. nyti.ms/1vbsfuQ

Nov 25, 2014

RT @dshultz14: I only cover the hardest hitting science stories. Here's 200 words on why dogs are such sloppy drinkers. news.sciencemag.org/physics/2014/1…



Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.

Email

For instructions on how to pitch Scott Hensley, email scotthensley@muckrack.com.


Share This Profile